Maize n Brew, a Michigan Wolverines community
Your best source for quality Michigan Wolverines news, rumors, analysis, stats and scores from the fan perspective.
News & Press - Maze Therapeutics
Nov 13, 2024 · Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney …
Maze Therapeutics (MAZE) Files for 7.8M Share IPO at $15-$17/sh
2 hours ago · FREE Breaking News Alerts from StreetInsider.com! E-mail Address. StreetInsider.com Top Tickers, 1/27/2025. 1. ... (NASDAQ: MAZE) has filed for 7,800,000 …
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
Jan 7, 2025 · (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public …
Maze Therapeutics Announces Oversubscribed $115 Million …
Dec 3, 2024 · MZE829, an oral, APOL1 inhibitor, is being evaluated as a treatment for APOL1 kidney disease (AKD), including in patients with focal segmental glomerulosclerosis (FSGS), …
News Archive | Maze Therapeutics
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for …
Maze Therapeutics Inc (MAZE) Stock Price, Trades & News
1 hour ago · Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients …
Kidney disease drugmaker Maze files for IPO | BioPharma Dive
Jan 8, 2025 · Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the year, depending on how quickly the deal comes …
Maze Therapeutics raises $115m to advance kidney disease …
Dec 4, 2024 · Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782. The financing round …
Endpoints News: Maze Therapeutics Spins Out Two New …
Just under two years after bursting onto the scene with close to $200 million, Maze Therapeutics is spinning out two new companies, focusing its human genetics and functional genomics …